Phase II trial of esorubicin (4′ deoxydoxorubicin, DxDx) in patients with small cell lung cancer Journal Article


Authors: Rigas, J. R.; Kris, M. G.; Gralla, R. J.; Heelan, R. T.; Marks, L. D.
Article Title: Phase II trial of esorubicin (4′ deoxydoxorubicin, DxDx) in patients with small cell lung cancer
Abstract: Esorubicin (4′-deoxydoxorubicin or DxDx) is an analog of doxorubicin with preclinical antitumor activity and no significant cardiotoxicity in model systems. Eleven patients with small cell lung cancer who had previously received chemotherapy were given esorubicin (25 mg/m2 intravenously) every 3 weeks. No major objective responses were observed (95% confidence limits: 0-25%). Nine of the 11 patients had grade 2 or greater toxicity, with 55% of the patients experiencing grade 3 or greater toxicity [myelosuppression (4/11), anemia (2/11) or elevated liver enzymes (3/11)]. Nausea, vomiting, alopecia and intravenous site phlebitis were also seen. Three of the 11 patients received 3 or more course of esorubicin without evidence of significant cardiotoxicity. At this dose and shedule, no significant antitumor response were seen in this population of patients. Esorubicin, with this low response rate and significant toxicity, appears to be of limited utility in this disease. © 1991 Kluwer Academic Publishers.
Keywords: adult; clinical article; aged; doxorubicin; phase 2 clinical trial; anemia; bone marrow suppression; lung neoplasms; lung cancer; antibiotics, antineoplastic; alopecia; intravenous drug administration; small cell carcinoma; small cell lung cancer; carcinoma, small cell; phase ii trial; middle age; drug evaluation; human; male; female; priority journal; article; support, non-u.s. gov't; support, u.s. gov't, p.h.s.; esorubicin; deoxydoxorubicin
Journal Title: Investigational New Drugs
Volume: 9
Issue: 2
ISSN: 0167-6997
Publisher: Springer  
Date Published: 1991-05-01
Start Page: 187
End Page: 190
Language: English
DOI: 10.1007/bf00175087
PUBMED: 1651908
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 27 September 2019 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Mark Kris
    869 Kris
  2. Robert T Heelan
    140 Heelan
  3. Linda Marks
    10 Marks
  4. James R. Rigas
    33 Rigas
  5. Richard J. Gralla
    69 Gralla